Skip to main
DWTX
DWTX logo

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics is focused on developing innovative antiviral therapies aimed at conditions like fibromyalgia and long COVID, with notable product candidates including IMC-1 and IMC-2. The company recently entered a licensing agreement with Serpin Pharma for the global rights to SP16 for cancer-related pain, indicating a strategic expansion of its therapeutic portfolio. Additionally, projections of increased future revenues from this new asset have led to an upward adjustment in the company's price target, reflecting a positive outlook for its financial performance.

Bears say

Dogwood Therapeutics Inc, a biotechnology company in the development stage, is focused on advancing antiviral therapies for diseases related to viral-triggered immune responses, including fibromyalgia and long COVID. The company is developing two product candidates, IMC-1 and IMC-2, which aim to address herpesvirus activation, yet their market viability remains uncertain due to the competitive and often unpredictable nature of pharmaceutical development. Additionally, the financial metrics suggest a lack of revenue generation and substantial funding needs, raising concerns about the company’s ability to sustain operations and bring its products to market effectively.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.